Apparatus and methods for stimulating revascularization and/or tissue growth

Apparatus and methods for stimulating revascularization and tissue growth are provided using an apparatus having a directable end region carrying a tissue piercing end effector. The apparatus optionally includes electrodes for depositing RF energy to form a controlled degree of scar tissue formation, means for delivering a controlled amount of a bioactive agent at the treatment site, or both.

Skip to: Description  ·  Claims  ·  References Cited  · Patent History  ·  Patent History
Description
REFERENCE TO RELATED APPLICATIONS

The present application is a continuation-in-part application of commonly assigned U.S. patent application Ser. No. 08/863,791, now U.S. Pat. No. 5,931,848, Ser. No. 08/863,877, now U.S. Pat. No. 5,910,150, and Ser. No. 08/863,925, now U.S. Pat. No. 5,941,839, all filed May 27, 1997. The present application is a continuation-in-part application of commonly assigned U.S. patent application Ser. No. 08/863,791, now U.S. Pat. No. 5,931,848, and Ser. No. 08/863,877, now U.S. Pat. No. 5,910,150, and Ser. No. 08/863,925, now U.S. Pat. No. 5,941,893, all filed May 27, 1997, all of which claim the benefit of the filing date of U.S. provisional patent application Ser. No. 60/032,196, filed Dec. 2, 1996.

FIELD OF THE INVENTION

The present invention relates to apparatus and methods for stimulating revascularization and tissue growth in an interior region of an organ or vessel, such as the heart. More particularly, the present invention provides a device that enables a clinician to stimulate a healing response, or deposit a bioactive agent at, a series of sites within in interior region of an organ or vessel to stimulate revascularization.

BACKGROUND OF THE INVENTION

A leading cause of death in the United States today is coronary artery disease, in which atherosclerotic plaque causes blockages in the coronary arteries, resulting in ischemia of the heart (i.e., inadequate blood flow to the myocardium). The disease manifests itself as chest pain or angina. In 1996, approximately 7 million people suffered from angina in the United States.

Coronary artery bypass grafting (CABG), in which the patient's chest is surgically opened and an obstructed artery replaced with a native artery harvested elsewhere, has been the conventional treatment for coronary artery disease for the last thirty years. Such surgery creates significant trauma to the patient, requires long recuperation times, and causes a great deal of morbidity and mortality. In addition, experience has shown that the graft becomes obstructed with time, requiring further surgery.

More recently, catheter-based therapies such as percutaneous transluminal coronary angioplasty (PTCA) and atherectomy have been developed. In PTCA, a mechanical dilatation device is disposed across an obstruction in the patient's artery and then dilated to compress the plaque lining the artery to restore patency to the vessel. Atherectomy involves using an end effector, such as a mechanical cutting device (or laser) to cut (or ablate) a passage through the blockage. Such methods have drawbacks, however, ranging from re-blockage of dilated vessels with angioplasty to catastrophic rupture or dissection of the vessel during atherectomy. Moreover, these methods may only be used for that fraction of the patient population where the blockages are few and are easily accessible. Neither technique is suitable for the treatment of diffuse atherosclerosis.

A more recent technique which holds promise for treating a larger percentage of the patient population, including those patients suffering from diffuse atherosclerosis, is referred to as transmyocardial revascularization (TMR). In this method, a series of channels are formed in the left ventricular wall of the heart. Typically, between 15 and 30 channels about 1 mm in diameter and up to 3.0 cm deep are formed with a laser in the wall of the left ventricle to perfuse the heart muscle with blood coming directly from the inside of the left ventricle, rather than traveling through the coronary arteries. Some researchers believe that the resulting channels improve perfusion of the myocardium with oxygenated blood. Apparatus and methods have been proposed to create such channels both percutaneously and intraoperatively (i e., with the chest opened).

U.S. Pat. No. 5,389,096 to Aita et al. describes a catheter-based laser apparatus for use in percutaneously forming channels extending from the endocardium into the myocardium. The catheter includes a plurality of control lines for directing the tip of the catheter. As the laser ablates the tissue during the channel forming process, the surrounding tissue necroses, resulting in fibroid scar tissue surrounding the channels. U.S. Pat. No. 5,380,316 to Aita et al. describes an intraoperative laser-based system for performing TMR.

U.S. Pat. No. 5,591,159 to Taheri describes mechanical apparatus for performing TMR comprising a catheter having an end effector formed from a plurality of spring-loaded needles. The catheter first is positioned percutaneously Within the left ventricle. A plunger is then released so that the needles are thrust into the endocardium. The needles core out small channels that extend into the myocardium as they are withdrawn. The patent suggests that the needles may he withdrawn and advanced repetitively at different locations under fluoroscopic guidance. The patent does not appear to address how tissue is ejected from the needles between the tissue-cutting steps

Although it is generally agreed that TMR benefits many patients, researchers do not agree upon the precise mechanism by which TMR provides therapeutic benefits. One theory proposes that TMR channels remain patent for long periods of time, and provide a path by which oxygenated blood perfuses the myocardium. However, relatively recent histological studies indicate that TMR channels may close within a short time following the procedure. For example, Fleischer et al., in “One-Month Histologic Response Of Transmyocardial Laser Channels With Molecular Intervention,” Ann. Soc. Thoracic Surg., 62:1051-58 (1996), evaluated histologic changes associated with laser TMR in a 1-month nonischemic porcine model, and was unable to demonstrate channel patency 28 days after TMR.

Other researchers have observed that in laser-based TMR patients, there appears to he enhanced vascularization of the tissue on the margins of the scar tissue resulting from the laser channel-forming process. It has therefore been hypothesized that the act of causing trauma to portions of the myocardium may invoke a regenerative process, that enhances the development of neovascularization and endothelialization in the tissue.

To investigate these alternative theories, researchers have studied the use of gene therapy in promoting blood vessel growth in the tissue surrounding laser TMR channels. In one study, researchers intraoperatively administered a single dose of vascular endothelial growth factor (VEGF) at the time of laser TMR. Although the study showed no significant increase in myocardial vascularity, the researchers hypothesized that a longer duration of VEGF residence may be necessary to stimulate angiogenesis.

In view of the foregoing, it would be desirable to provide apparatus and methods for stimulating revascularization and tissue growth in an interior region of an organ or vessel, such as the heart, by stimulating native revascularization and tissue growth mechanisms.

It would also be desirable to provide apparatus and methods for stimulating revascularization and tissue growth by controlling the placement and size of tissue treatment sites, thereby resulting in a controlled degree of scar tissue formation.

It would be still further desirable to provide apparatus and methods for stimulating revascularization and tissue growth by depositing a controlled amount of a bioactive agent, such as an angiogenic growth factor, at the treatment sites.

SUMMARY OF THE INVENTION

In view of the foregoing, it is an object of this invention to provide apparatus and methods for stimulating revascularization and tissue growth in an interior region of an organ or vessel, such as the heart, by stimulating native revascularization and tissue growth mechanisms.

It is another object of the present invention to provide apparatus and methods for stimulating revascularization and tissue growth by controlling the placement and size of tissue treatment sites, thereby resulting in a controlled degree of scar tissue formation.

It is a still further object of this invention to provide apparatus and methods for stimulating revascularization and tissue growth by depositing a controlled amount of a bioactive agent, such as a drug or an angiogenic growth factor, at the treatment sites.

These and other objects of the present invention are accomplished by providing apparatus having a directable end region carrying an end effector that induces trauma at a treatment site to stimulate revascularization. The apparatus may optionally include electrodes for depositing RF energy to form a controlled degree of scar tissue formation, means for depositing a controlled amount of a bioactive agent at the treatment site, or both.

Apparatus constructed in accordance with the present invention comprises a catheter having a longitudinal axis, an end region that is deflectable relative to the longitudinal axis, and a tissue piercing end effector. The end effector may optionally include an RF electrode for causing a controlled degree of necrosis at a treatment site, the capability to deposit a controlled amount of a bioactive agent at the treatment site, or both.

Methods of using the apparatus of the present invention to stimulate revascularization and/or tissue growth are also provided.

BRIEF DESCRIPTION OF THE DRAWINGS

Further features of the invention, its nature and various advantages will be more apparent from the accompanying drawings and the following detailed description of the preferred embodiments, in which:

FIG. 1 is a view of an illustrative embodiment of apparatus constructed in accordance with the present invention;

FIG. 2 is a perspective view of an end region and end effector of the apparatus of FIG. 1;

FIG. 3 is schematic view of an illustrative arrangement for driving the end effector of FIG. 1;

FIG. 4 is a partial side view of the end effector of the apparatus of FIG. 1;

FIG. 5 is a schematic view of an alternative illustrative arrangement for driving an end effector adapted to deliver a bioactive agent,

FIG. 6 is a partial side view of the end effector of the apparatus of FIG. 5;

FIGS. 7A to 7C are views illustrating operation of the apparatus of FIG. 1,

FIG. 8 is a schematic view of another alternative arrangement for driving the end effector of the apparatus of FIG. 1;

FIG. 9 is a schematic view of a yet another further alternative arrangement for driving an end effector constructed in accordance with the present invention;

FIGS. 10A and 10B are, respectively, partial side sectional views illustrating operation of another end effector of the present invention;

FIGS. 11A and 11B are, respectively, a partial side sectional view and cross-sectional view of a further alternative embodiment of an end effector of the present invention; and

FIGS. 12A to 12D are views illustrating operation of the end effector of FIGS. 11 to deposit a pellet of a bioactive agent at a treatment site.

 DETAILED DESCRIPTION OF THE INVENTION

The present invention relates generally to apparatus and methods for treating a plurality of tissue sites within a vessel or organ to stimulate tissue growth and revascularization. The apparatus of the present invention comprises a catheter having an end region that may be selectively articulated to a position at an angle relative to the longitudinal axis of the catheter, including a position substantially orthogonal to the longitudinal axis.

The end region carries a tissue piercing end effector to induce trauma to stimulate native tissue repair and revascularization mechanisms. The end effector may optionally include an RF electrode to cause a controlled degree of necrosis, means for depositing a controlled amount of a bioactive agent at the treatment site, or both. The deflectable end region of the catheter provides precise control over the location of the end region, and thus, the end effector.

Referring to FIG. 1, illustrative apparatus 20 constructed in accordance with the present invention is described. Apparatus 20 comprises catheter 21 having deflectable end region 22, end effector 23 and handle 24, cable 25 and controller 26. Apparatus 20 is coupled via cable 25 to controller 26. End effector 23, described in greater detail hereinbelow, pierces myocardial tissue, with or without coring, to attain a treatment goal.

End region 22 includes one or more control wires 27 disposed for sliding movement within catheter 21, such as described in U.S. Pat. Nos. 5,389,073 and 5,330,466 to Imran, which are incorporated herein by reference. Application of a predetermined proximal force on control wire 27 (indicated by arrow A), deflects end region 23 a predetermined amount (shown in dotted lines in FIG. 2). Accordingly, end region 23 may be moved between a transit position, parallel to longitudinal axis 28 of catheter 21 and a working position (as shown) substantially orthogonal to longitudinal axis 28.

In a preferred embodiment, wherein the end effector comprises a flexible wire having a sharpened tip, controller 26 includes a hydraulic or pneumatic piston, valve assembly and control logic for extending and retracting the end effector beyond the distal endface of end region 23 responsive to commands input at handle assembly 24 or a footpedal (not shown) Controller 26 optionally may further contain RF generator circuitry for energizing electrodes disposed on the end effector to cause a controlled degree of necrosis at the treatment site. Alternatively, or in addition, controller 26 may include a source of a bioactive agent, and means for delivering controlled amounts of the bioactive agent to the treatment site.

Referring now to FIG. 3, end effector 23 and controller 26 of a first embodiment are described. In FIG. 4, most of catheter 21 and handle 24 have been omitted for clarity. End effector 23 comprises tissue piercing cone 41 having optional first and second RF electrodes 42a and 42b, respectively. End effector preferably comprises a rigid material that retains a sharp tip, such as stainless steel Drive shaft 43, which extends through cable 25 of FIG. 1, is coupled to end effector 23 via flexible coupling 44 at its distal end, and to piston 45 at its proximal end. Drive shaft 43 is disposed for reciprocation in end region 22 responsive to movement of piston 45. Drive shaft 43 may comprise a single or braided plastic or metal alloy wire, while flexible coupling 44 comprises a sturdy but flexible plastic or metal alloy.

Piston 45 is enclosed within cylinder 46 for proximal and distal movement. High pressure source 47 is connected to valve 48 and pressure lines 49a and 49b; low pressure source 50 is connected to valve 51 and pressure lines 52a and 52b. Pressure lines 49a and 52a communicate with proximal volume 53a of cylinder 46, whereas pressure lines 49b and 52b communicate with distal volume 53b of cylinder 46. Valves 48 and 51 are synchronized so that when high pressure source 47 is coupled to pressure line 49a (but not 49b), low pressure source 50 is coupled to line 52b (but not 52a), thus driving piston 45 in the distal direction.

Likewise, when valve 48 couples high pressure source 47 to pressure line 49b (but not 49a), and valve 51 couples low pressure source 50 to line 52a (but not 52b), piston 45 is driven in the proximal direction. Valves 48 and 51 are coupled by wiring (not shown) to control logic 54, which actuates the valves responsive to control commands received from handle assembly 26 or a footpedal (not shown). Cylinder 46 may employ any suitable medium for moving piston 45, and may be either pneumatic or hydraulic.

Controller 26 optionally includes RF generator circuitry 55 which generates a high frequency (e.g., greater than 100 MHZ) voltage signal. RF generator circuitry 55 is coupled via suitable bushings and conductors (not shown) to electrodes 42a and 42b. Electrodes 42a and 42b may be arranged to conduct current through tissue located in contact them, in a bipolar mode, or may conduct current through the tissue and to a ground plate (not shown) in a monopolar mode. In embodiments of controller 26 where RF generator circuitry 55 is provided, control logic 54 may be programmed to energize electrodes 42a and 42b when piston 45 has attained its maximum distal stroke. Control logic 54 may energize electrodes 42a and 42b for a user selected interval to provide a controlled degree of necrosis in the tissue surrounding the treatment site created by end effector 23.

Referring now also to FIG. 6 3, when piston 45 is driven in the distal direction, end effector 23 extends beyond the distal endface of catheter 21 and pierces and extends into tissue T. End effector 23 thereby induces trauma to tissue T in the form of needle track N. If electrodes 42a and 42b and RF generator circuitry 55 are provided, control logic 55 may energize the electrodes to cause necrosis of tissue T in a region R surrounding the end effector. Control logic 54 then reverses the orientation of valves 48 and 51, thus causing end effector 23 to be retracted from tissue T and into end region 22.

Applicants expect that the trauma caused by needle track N will stimulate naturally occurring mechanisms to repair the wound at the treatment site. It is further expected that by generating a matrix of treatment sites, a network of small vessels may become established in the tissue as it heals. In addition, by providing a controlled degree of necrosis, a preselected degree of scar tissue may be induced, thus mimicking the conditions observed to induce revascularization at the margins of laser-formed TMR channels.

With respect to FIGS. 5 and 6, an alternative embodiment of the end effector and controller of the present invention is described. Once again, catheter 21 (except for end region 22) and handle 24 have been omitted from FIG. 5 for clarity End effector 60 comprises non-coring tissue piercing cone 61 affixed to drive shaft 62. Drive shaft 62 includes lumen 63, and extends through cable 25 of FIG. 1 Drive shaft 62 is coupled to piston 64 at its proximal end, and is disposed for reciprocation in the guide tube (not shown) responsive to movement of piston 64. Drive shaft 62 preferably comprises a thin-walled but flexible plastic or metal alloy tube. End effector 60 may optionally include electrodes 65a and 65b for applying an RF voltage potential to the tissue to cause a controlled degree of necrosis, as described hereinabove with respect to the embodiment of FIGS. 3 and 4.

Piston 64 is enclosed within a cylinder in controller 66 for proximal and distal movement. High pressure source 67 is connected to valve 68 and pressure lines 69a and 69b; low pressure source 70 is connected to valve 71 and pressure lines 72a and 72b. Pressure lines 69a and 72a communicate with proximal volume 73a of the cylinder, whereas pressure lines 69b and 72b communicate with distal volume 73b of the cylinder Valves 68 and 71 are synchronized as described hereinabove with respect to like components of FIG. 4, so as to extend and retract end effector 60 under the control of control logic 74 responsive to control commands received from handle assembly 26.

Drive shaft 62 includes a plurality of outlet ports 75 located adjacent to cone 61 and a plurality of inlet ports 76 disposed in chamber 77. Chamber 77 contains bioactive agent 80 suspended in a biocompatible high viscosity liquid or paste, and is selectively pressurized by pressure source 78. Bioactive agent 80, may comprise a drug or an angiogenic growth factor, for example, vascular endothelial growth factor (VEGF), fibroblast growth factor, type I (FGF-I) or type II (FGF-II), a gene vector, cardio myocytes, or other suitable agent for stimulating tissue growth and/or revascularization.

Inlet ports 76 and outlet ports 75 communicate with lumen 63. In accordance with one aspect of the present invention, when high pressure source 78 is actuated to pressurize chamber 77, a controlled amount of bioactive agent 80 is injected into inlet ports 76 of lumen 63. This in turn causes an equal amount of bioactive agent 80 to be expelled through outlet ports 75 of end effector 60 into the adjacent tissue. Control logic 74 preferably is programmed to actuate high pressure source 78 when piston 64 has attained its maximum distal stroke. Controller 66 may in addition include an RF generator circuitry similar to RF generator circuitry 55 of the embodiment of FIG. 3 for energizing electrodes 65a and 65b.

With respect to FIG. 6, when piston 64 is driven in the distal direction, end effector 60 extends beyond the distal endface of the catheter and pierces and extends into tissue T. End effector 60 thereby causes trauma to tissue T in the form of needle track N. Once end effector 60 reaches its maximum depth, control logic 74 actuates high pressure source 78, causing a controlled amount of bioactive agent 80 to be expelled through outlet ports 75 into the tissue.

If the bioactive agent exits the ports with sufficiently high velocity, it is expected that the bioactive agent will form pockets 81 in the tissue. Alternatively, if the bioactive agent exits outlet ports 75 at lower velocity, it is expected that the bioactive agent will form a layer that coats the interior surface of needle track N. Once the bioactive agent has been deposited, control logic 74 reverses the orientation of valves 68 and 71, thus causing end effector 60 to be retracted from tissue T and into the end region of the catheter. If provided, RF electrodes 65a and 65b may be activated to cauterize tissue in the vicinity of needle track N.

As described hereinabove, applicants expect that the trauma caused by needle track N will stimulate the release of naturally tissue regenerative mechanisms to repair the wound at the treatment site. Moreover, the introduction of bioactive agent 80 along needle track N is expected to further stimulate revascularization By generating a matrix of treatment sites within which a bioactive agent has been deposited, it may be possible to promote the development of a network of small vessels that will perfuse the tissue.

Referring now to FIGS. 7A–7C, operation of apparatus 20 in the context of treating a series of treatment sites to stimulate revascularization in left ventricular myocardium is described. In FIG. 7A, end region 22 of apparatus 20 is shown positioned in a patient's left ventricular cavity, using techniques which are per se known. Specifically, end region 22 of apparatus 20 is inserted via a femoral artery, and is maneuvered under fluoroscopic guidance in a retrograde manner up through the descending aorta, through aortic arch 201, and down through ascending aorta 202 and aortic valve 203 into left ventricle 204. As will of course be understood, insertion of apparatus 20 into the left ventricle is with end region 22 in its transit position.

Previously known imaging techniques, such as ultrasound, MRI scan, CT scan, or fluoroscopy, may be used to verify the location of the end region 22 within the heart. Alternatively, means may be provided in end region 22 for emitting an ultrasonic signal which is detectable using an ultrasound imaging system outside of the patient. For example, a piezo-electric transducer may be affixed to the tip of the catheter and tuned to a frequency of a color Doppler ultrasound imaging system so as to appear as a bright orange or yellow spot on the display of the ultrasound system. Yet another way to detect the location of end region 22 is by pinpointing the delay time of an EKG signal at the point of detection, using an electrode disposed in end region 22. By looking at the morphology as well as the temporal characteristics of the EKG signal, the vertical position of the catheter within the heart chamber may be determined.

Referring to FIG. 7B, once end region is located adjacent a desired portion of the endocardial surface, end region 22 is deflected to its working position, for example, by operating control wire 27. In this manner end effector 23 is disposed against a surface of the endocardium to be treated.

Controller 26 is then actuated to cause end effector 23 to pierce and extend into the interior of left ventricular wall 206. When the end effector reaches its maximum depth, a burst of RF energy may be applied, if desired, to necrose a depth of tissue, an amount of a bioactive agent may be deposited at the treatment site, or both. Controller 26 then withdraws end effector 23 from the tissue.

As shown in FIG. 7C, a series of vertically aligned spaced-apart needle tracks 207 may he formed in left ventricular wall 206 by repositioning end region 22 using control wire 27. End effector 23 is then advanced to form a further needle track 207 in the tissue.

The foregoing methods enable a matrix of channels to be formed illustratively in the left ventricular wall. It will of course be understood that the same steps may be performed in mirror image to produce a series of needle tracks in the septal region. It is believed that the needle tracks may have a beneficial effect if formed anywhere on the walls of the heart chamber, including the septum, apex and left ventricular wall; the above-described apparatus provides this capability

In addition, a stabilization assembly may be employed, for example, as described in copending, commonly assigned U.S. patent application Ser. No. 08/863,877, filed May 27, 1997, to counteract any reaction forces generated by operation of end effector 23.

In FIG. 8, an alternative arrangement for driving the end effector of the present invention is described. In controller 130 of FIG. 8, the piston and cylinder of controller 26 of FIG. 1 are replaced with a mechanical drive system. As in FIGS. 3 and 4, most of the catheter and handle have been omitted for clarity. End effector 131 comprises non-coring sharpened tip 132 coupled to drive shaft 133. Drive shaft 133 is coupled at its proximal end to push rod 134. Push rod 134 is biased against eccentric cam 135 by spring 136. Cam 135 is mounted on motor 137, which rotates cam 135 through one revolution responsive to commands from control logic 138. Control logic 138, in turn, actuates motor 137 responsive to commands received, for example, by a button on handle 24 (see FIG. 1). Thus, controller 130 extends and retracts end effector 131 to create a needle track in the tissue.

As will of course be apparent to one of skill in designing catheter-based systems, controller 130 may optionally include either the RF generator circuitry and electrodes of the embodiment of FIG. 3, the bioactive agent delivery system described with respect to the embodiment of FIG. 5, or both. As will be further apparent, the specific drive arrangements described hereinabove are intended to be illustrative, and other mechanisms may be readily employed. For example, the specific configuration of the pressure sources, pressure lines and the valves in FIGS. 3 and 5 are intended to be merely illustrative. Equivalent mechanisms for extending and retracting the end effector may be readily employed within the scope of the present invention. Thus, for example, the end effector may be spring loaded so as to be biased in the extended position and reset after having been extended to form each needle track.

Referring now to FIGS. 9, 10A and 10B, a further alternative embodiment of a drive system and end effector suitable for use in the present invention are described. In apparatus 140 of FIG. 9, it is again to be understood that the handle and most of the catheter have been omitted for clarity In apparatus 140, a manual drive arrangement has been substituted for the controller of the previously described embodiments. In particular, end effector 142 comprises tip 143 having aperture 144 coupled to the distal end of drive shaft 145. Proximal end 146 of drive shaft 145 includes actuator ring 147, and proximal end 148 of catheter 141 includes rings 149. As will be apparent, drive shaft 144 may be driven in the distal direction to extend end effector 142 by squeezing actuator ring 147 towards rings 149.

With respect to FIG. 10A, drive shaft 145 includes lumen 150 and push wire 151 disposed within lumen 150. Push wire 151 terminates at its proximal end in a plurality of fine wires 152. Wires 152 may comprise, for example, nickel-titanium, and are constructed so that when they extend through aperture 144, the wires diverge (see FIG. 10B). Push wire 151 extends through lumen 150 of drive shaft 145 and terminates in button 153. By gripping flange 154 provided on proximal end 146 of drive shaft 145, button 153 may be depressed toward flange 154, thereby extending wires 152 through aperture 144.

FIG. 10A shows end effector 142 extended to pierce and extend into tissue T to form needle track N, for example, by squeezing actuator ring 147 towards ring 149. As will of course be understood, this step occurs after the catheter has been disposed within an organ or vessel as described above with respect to FIGS. 7A and 7B. FIG. 10B illustrates that extension and retraction of wires 152 generates a matrix of additional needle tracks N′ Applicant expects that, like the application of RF energy to form a controlled layer of scar tissue, or the deposition of an amount of a bioactive agent, the matrix of needle tracks N′ will further stimulate revascularization in the tissue

With respect to FIGS. 11A and 11B, an alternative embodiment of an end effector is described for depositing a bioactive agent in a pelletized form. In FIGS. 11, it is to be understood that the handle assembly and most of the catheter have been omitted. End effector 160 comprises tube 161 including beveled non-coring tip 162 mounted in distal end 163 of catheter 164. Push rod 165 is disposed for reciprocation in lumen 166 of tube 161. As shown in FIG. 11B, catheter 164 includes lumen 167 in which tube 161 is disposed, and lumen 168 through which bioactive pellets 170, illustratively, spherical beads, are advanced to end effector 160. Lumen 168 includes passageway 169 through which a pellet passes to engage push rod 165 for delivery.

In accordance with one aspect of the present invention, pellets 170 comprise a bioactive agent, as described hereinabove, disposed in a biodegradable binder, such as polycaprolactone or polylactic acid. Pellets 170 are sized to advance through lumen 168 freely and without bunching, so that when posh rod is retracted in the proximal direction past the proximal edge of passageway 169, a single pellet 170 passes into lumen 166 of tube 161. While pellets 170 are illustrative spherical, it is to be understood that the bioactive agent may be readily formed into any of a number of other shapes, such as rods, cones, granules, etc., and that the above-described delivery system may be readily adapted to such other pelletized forms.

Referring now to FIGS. 12A to 12D, operation of the apparatus of FIGS. 11 is described. Apparatus including end effector 160 first is disposed within an internal organ, such as the left ventricle, as described hereinabove with respect to FIGS. 7A to 7C. End effector 160 then is oriented so as to be positioned at a desired angle, e.g. perpendicular, to tissue T to be treated. While end effector 160 is being maneuvered into position, posh rod 165 is extended so that distal endface 171 extends past the distal edge of passageway 169, thereby confining pellets 170 within lumen 168. End effector 160 is urged in the distal direction to form needle track N, and so that tip 162 penetrates tissue T until catheter 164 abuts against the endocardium (shown in FIG. 12A).

Push rod 165 then is retracted in the proximal direction, so that distal endface 171 is positioned proximally of the proximal edge of passageway 169. This in turn permits a single pellet 170 to advance through passageway 169 into lumen 166, as shown in FIG. 12B. Because pellets 170 are preferably only slightly smaller than the diameter of lumen 166, when a single pellet 170 has advanced into lumen 166, it will block other pellets from passing through passageway 169 into lumen 166. Alternatively, pellets 170 may be sized so that a predetermined number of pellets pass into lumen 166 each time push rod 165 is retracted proximally.

Push rod 165 then is driven in the distal direction, urging pellet 170 to the end of needle track N, as illustrated in FIG. 12C If RF electrodes are provided on tip 162, such electrodes may be energized to necrose a predetermined thickness of tissue in the vicinity of tip 162. End effector 160 then is withdrawn, leaving pellet 170 within needle track N in tissue T. As described hereinabove, pellet 170 preferably comprises a biodegradable substance that elutes a suitable bioactive agent into the tissue surrounding the pellet over a preselected period of time. It is expected that by depositing a bioactive substance within tissue T, tissue revascularization and growth may be stimulated, as described hereinabove. End effector 160 then is moved to another location and the foregoing process repeated to seed a plurality of pellets 170.

While preferred illustrative embodiments of the invention are described above, it will he apparent to one skilled in the art that various changes and modifications may be made therein without departing from the invention, and the appended claims are intended to cover all such changes and modifications that fall within the true spirit and scope of the invention.

Claims

1. Apparatus for treating an interior region of a cardiac chamber, the apparatus comprising:

a catheter configured for insertion into a cardiac chamber, the catheter having a deflectable end region;
an end effector disposed within distal to the delectable end region, the end effector adapted to form a needle track at a treatment site in an interior region of the cardiac chamber, the end effector movable between a first position, wherein the end effector is retracted within the end region, and a second position, wherein the end effector is extended beyond a distal endface of the catheter; and
means for moving the end region between the first and second positions, wherein the end effector further comprises means for depositing a controlled amount of a bioactive agent at the treatment site and wherein the catheter has a plurality of lumens, one of which contains the bioactive agent and wherein the catheter has a conductor extending from a proximal end of the catheter to an electrode which is distal to the deflectable end region.

2. The apparatus of claim 1 wherein the end effector comprises a non-coring sharpened tip.

3. The apparatus of claim 1 wherein the end effector further comprises an electrode adapted to deliver RF energy to the treatment site.

4. The apparatus of claim 1 wherein the end effector further comprises a plurality of fine wires, the fine wires movable between a retracted position and an extended position, the plurality of fine wires forming a matrix of additional needle tracks at the treatment site when extended.

5. The apparatus of claim 1 wherein the end effector is coupled to a drive shaft, the apparatus further comprising a controller including a hydraulic mechanism coupled to the drive shaft to extend and retract the end effector.

6. The apparatus as defined in claim 1 wherein the end effector is coupled to a drive shaft, the apparatus further comprising a controller including a pneumatic mechanism coupled to the drive shaft to extend and retract the end effector.

7. The apparatus as defined in claim 1 wherein the end effector is coupled to a drive shaft, the apparatus further comprising a manually actuated mechanism coupled to the drive shaft to extend and retract the end effector.

8. Apparatus for treating an interior region of a cardiac chamber, the apparatus comprising:

a catheter having a deflectable end region;
an end effector adapted to form a needle track at a treatment site in an interior region of the cardiac chamber, the end effector movable between a first position, wherein the end effector is retracted within the end region, and a second position, wherein the end effector is extended beyond a distal endface of the catheter; and
means for depositing a bioactive agent in the needle track when the end effector is in the second position and wherein the catheter has a plurality of lumens, one of which contains the bioactive agent and wherein the catheter has a conductor extending from a proximal end of the catheter to an electrode which is distal to the deflectable end region.

9. The apparatus of claim 8 wherein the end effector comprises a non-curing sharpened tip.

10. The apparatus of claim 8 wherein the end effector further comprises an electrode adapted to deliver RF energy to the treatment site.

11. The apparatus of claim 10 wherein the bioactive agent is a fluid and the means for depositing comprises supplies the fluid to the end effector under pressure.

12. The apparatus of claim 8 wherein bioactive agent has a pellet form and the means for depositing the bioactive agent comprises a push rod.

13. A method of treating an interior region of a cardiac chamber the method comprising:

providing apparatus having a catheter adapted for insertion into a cardiac chamber, the catheter having a deflectable end region including an end effector adapted to form a needle track at a treatment site in an interior region of the cardiac chamber, wherein the catheter has a plurality of lumens, one of which contains a bioactive agent, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to the end effector;
inserting the apparatus within a cardiac chamber;
deflecting the end region to dispose the end effector at a selected orientation relative to an endocardial surface;
actuating the end effector to form a needle track in an interior region of the cardiac chamber at a treatment site; and
delivering a controlled amount of a the bioactive agent at the treatment site, wherein the needle track, after the delivering, is substantially closed onto the bioactive agent.

14. The method of claim 13 further comprising delivering RF energy to the treatment site to create a controlled depth of necrosis at the treatment site.

15. The method of claim 13 wherein delivering a controlled amount of a bioactive agent at the treatment site further comprises injecting the bioactive agent under pressure sufficient to form a pocket of bioactive agent in the tissue.

16. The method of claim 13 wherein delivering a controlled amount of a bioactive agent at the treatment site further comprises injecting a pellet comprising a bioactive agent.

17. The method as defined in claim 13 wherein the end effector further comprises a plurality of fine wires, the fine wires movable between a retracted position and an extended position, the method further comprising extending the plurality of fine wires to form a matrix of additional needle tracks at the treatment site.

18. The method as defined in claim 13 further comprising, following delivering a controlled amount of a bioactive agent at the treatment site:

translating the end region to relocate the end effector; and
repeating actuation of the end effector.

19. An apparatus, comprising:

a catheter configured for percutaneous insertion into a cardiac tissue, the catheter having a proximal region, a steerable distal region, and a lumen extending from the proximal region to the steerable distal region;
a needle disposed distal to the steerable distal region and movable between a first position, wherein the needle is retracted within the distal region, and a second position, wherein the needle is extended beyond the distal region; and
a controller coupled near the proximal region and having a source of a bioactive agent, wherein the controller mechanically measures a controlled amount of the bioactive agent, and wherein the bioactive agent is passed through the lumen, in fluid communication with the needle, for delivery into the cardiac tissue, wherein the needle further comprises a means for depositing the controlled amount of the bioactive agent into the cardiac tissue, and wherein the catheter has a plurality of lumens, one of which contains the bioactive agent and wherein the catheter has a conductor extending from a proximal end of the catheter to an electrode which is distal to the steerable distal region.

20. The apparatus of claim 19, wherein the bioactive agent has a pellet form.

21. The apparatus of claim 19, wherein the bioactive agent has a fluid form.

22. The apparatus of claim 19, wherein the controller releases a plurality of discrete units of the bioactive agent through the lumen of the needle.

23. The apparatus of claim 22, wherein the plurality of discrete units of the bioactive agent comprises a predetermined amount of the bioactive agent.

24. The apparatus of claim 19, wherein the needle further comprises an electrode adapted to delivery RF energy to the cardiac tissue.

25. The apparatus of claim 19, wherein the controller comprises a chamber adapted to contain the bioactive agent.

26. The apparatus of claim 19, further comprising a mechanical driver coupled near the proximal region, wherein the mechanical driver retracts and extends the needle a controlled depth into the cardiac tissue.

27. An apparatus, comprising:

a catheter configured for percutaneous insertion into a cardiac tissue, the catheter having a proximal region, a steerable distal region, and a lumen extending from the proximal region to the steerable distal region;
a needle disposed distal to the steerable distal region and movable between a first position, wherein the needle is retracted within the distal region, and a second position, wherein the needle is extended beyond the distal region; and
a controller coupled near the proximal region and having a source of a bioactive agent, wherein the controller passes a predetermined amount of the bioactive agent through the lumen, in fluid communication with the needle, for delivery into the cardiac tissue, wherein the needle further comprises a means for depositing the predetermined amount of the bioactive agent into the cardiac tissue, and wherein the catheter has a plurality of lumens, one of which contains the bioactive agent and wherein the catheter has a conductor extending from a proximal end of the catheter to an electrode which is distal to the steerable distal region.

28. The apparatus of claim 27, wherein the bioactive agent has a pellet form.

29. The apparatus of claim 27, wherein the bioactive agent has a fluid form.

30. The apparatus of claim 27, wherein the controller mechanically measures a controlled amount of the bioactive agent.

31. The apparatus of claim 27, wherein the needle further comprises an electrode adapted to delivery RF energy to the cardiac tissue.

32. The apparatus of claim 27, further comprising a mechanical driver coupled near the proximal region, wherein the mechanical driver retracts and extends the needle a controlled depth into the cardiac tissue.

33. A method for delivering a bioactive agent to a patient's cardiac tissue, the method comprising:

providing a catheter adapted for percutaneous insertion into the cardiac tissue, the catheter having a steerable end region and a hollow needle adapted to deliver discrete units of a bioactive agent having a predetermined dosage and a push rod to push the discrete units, wherein the catheter has a plurality of lumens, one of which contains the bioactive agent, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to an electrode which is distal to the steerable end region;
inserting the catheter within the cardiac tissue;
steering the steerable end region to dispose the hollow needle at a selected orientation relative to an interior surface of the cardiac tissue; and
delivering and mechanically measuring a controlled amount of the bioactive agent to the cardiac tissue.

34. The method of claim 33, further comprising delivering a plurality of discrete units of the bioactive agent to the cardiac tissue.

35. The method of claim 33 wherein delivering comprises injecting the bioactive agent under pressure sufficient to form a pocket of the bioactive agent in the cardiac tissue.

36. The method of claim 33 wherein delivering comprises injecting the bioactive agent in a pellet form.

37. The method of claim 33 wherein delivering comprises injecting the bioactive agent in a fluid form.

38. The method of claim 33, further comprising delivering RF energy to the cardiac tissue.

39. The method of claim 33, further comprising mechanically retracting and extending the needle a controlled depth into the cardiac tissue.

40. A method for delivering a bioactive agent to a patient's cardiac tissue, the method comprising:

providing a catheter adapted for percutaneous insertion into the cardiac tissue, the catheter having a steerable end region and a needle adapted to deliver discrete units of a bioactive agent having a predetermined dosage, wherein the catheter has a plurality of lumens, one of which contains the discrete units, and a push rod to push the discrete units, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to an electrode coupled to the needle near the steerable end region;
inserting the catheter within the cardiac tissue;
steering the steerable end region to dispose the needle at a selected orientation relative to an interior surface of the cardiac tissue; and
mechanically delivering the predetermined dosage of the bioactive agent through the needle into the cardiac tissue using the push rod.

41. The method of claim 40, further comprising delivering a plurality of discrete units of the bioactive agent to the treatment site.

42. The method of claim 41, further comprising mechanically measuring a controlled amount of the bioactive agent.

43. The method of claim 41 wherein delivering comprises injecting the bioactive agent under pressure sufficient to form a pocket of the bioactive agent in the cardiac tissue.

44. The method of claim 41 wherein delivering comprises injecting the bioactive agent in a pellet form.

45. The method of claim 41 wherein delivering comprises injecting the bioactive agent in a fluid form.

46. The method of claim 41, further comprising delivering RF energy to the cardiac tissue.

47. The method of claim 40, further comprising mechanically driving the needle to control a penetration depth of the needle into the cardiac tissue.

48. An apparatus for delivering a bioactive agent to a patient's cardiac tissue, the apparatus comprising:

means for providing a catheter adapted for percutaneous insertion into the cardiac tissue, the catheter having a steerable end region and a hollow needle adapted to deliver discrete units of a bioactive agent having a predetermined dosage, wherein the catheter has a plurality of lumens, one of which contains the discrete units, and a push rod to push the discrete units, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to an electrode which is distal to the steerable end region;
means for inserting the catheter within the cardiac tissue;
means for steering the steerable end region to dispose the hollow needle at a selected orientation relative to an interior surface of the cardiac tissue; and
means for delivering and mechanically measuring a controlled amount of the bioactive agent.

49. An apparatus for delivering a bioactive agent to a patient's cardiac tissue, the apparatus comprising:

means for providing a catheter adapted for percutaneous insertion into the cardiac tissue, the catheter having a steerable end region and a needle adapted to deliver discrete units of a bioactive agent having a predetermined dosage, wherein the catheter has a plurality of lumens, one of which contains the discrete units, and a push rod to push the discrete units, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to an electrode which is distal to the steerable end region;
means for inserting the catheter within the cardiac tissue;
means for steering the steerable end region to dispose the needle at a selected orientation relative to an interior surface of the cardiac tissue; and
means for mechanically delivering the predetermined dosage of the bioactive agent through the needle into the cardiac tissue.

50. An apparatus, comprising:

a catheter configured for percutaneous insertion into a cardiac tissue, the catheter having a proximal region, a steerable distal region which is deflectable, and a lumen extending from the proximal region to the steerable distal region;
a needle disposed distal to the steerable distal region and movable between a first position, wherein the needle is retracted within the distal region, and a second position, wherein the needle is extended beyond the distal region and wherein the needle is deflectable within the steerable distal region; and
a controller coupled near the proximal region and having a source of a bioactive agent in the form of discrete units, wherein the controller passes a predetermined amount of the bioactive agent through the lumen, in fluid communication with the needle, for delivery into the cardiac tissue, wherein the needle further comprises a means for depositing the predetermined amount of the bioactive agent into the cardiac tissue, and wherein the catheter has a plurality of lumens, one of which contains the bioactive agent and wherein the catheter has a conductor extending from a proximal end of the catheter to an electrode which is distal to the steerable distal region.

51. The apparatus of claim 50, wherein the bioactive agent has a pellet form.

52. A method for delivering a bioactive agent to a patient's cardiac tissue, the method comprising:

providing a catheter adapted for percutaneous insertion into the cardiac tissue, the catheter having a steerable end region and a hollow needle adapted to deliver granules of a bioactive agent having a predetermined dosage, wherein the catheter has a plurality of lumens, one of which contains the granules, and a push rod to push the granules, wherein the catheter has a plurality of lumens, one of which contains the bioactive agent, wherein the catheter has a conductor extending from the proximal end of the catheter to the distal end of the catheter and the conductor is coupled to an electrode which is distal to the steerable end region;
inserting the catheter within the cardiac tissue;
steering the steerable end region to dispose the hollow needle at a selected orientation relative to an interior surface of the cardiac tissue; and
mechanically delivering a controlled amount of the granules using the push rod.

53. The method of claim 52, wherein the catheter includes a plurality of granules.

54. The method of claim 53, wherein mechanically delivering comprises separating a single granule from the plurality of granules.

55. The method of claim 54 additionally comprising inserting a single granule within the cardiac tissue.

56. The method of claim 52 additionally comprising inserting at least one granule into the cardiac tissue and wherein the mechanically delivering comprises measuring the controlled amount.

57. The method of claim 52, wherein inserting comprises inserting the hollow needle into the cardiac tissue.

58. The method of claim 57, wherein a portion of the catheter allows only the hollow needle to insert into the cardiac tissue.

59. The method of claim 57, wherein a path into the cardiac tissue is created by inserting the hollow needle.

60. The method of claim 59, wherein the path substantially closes after the hollow needle is withdrawn from the cardiac tissue such that the granule is in complete contact with the cardiac tissue.

Referenced Cited
U.S. Patent Documents
1162901 December 1915 Cantry et al.
2710000 June 1955 Cromer et al.
2749909 June 1956 Ullery et al.
3120845 February 1964 Horner
3470876 October 1969 Barchilon
3477423 November 1969 Griffith et al.
3557794 January 1971 Van Patten
3614953 October 1971 Moss
3692020 September 1972 Schied
3780246 December 1973 Beckering et al.
4207874 June 17, 1980 Choy
4362161 December 7, 1982 Reimels et al.
4381037 April 26, 1983 Cuneo
4461305 July 24, 1984 Cibley
4468224 August 28, 1984 Enzmann et al.
4479896 October 30, 1984 Antoniades
4576162 March 18, 1986 McCorkle
4578057 March 25, 1986 Sussman
4582056 April 15, 1986 McCorkle, Jr.
4600014 July 15, 1986 Beraha
4640296 February 3, 1987 Schnepp-Pesch et al.
4646738 March 3, 1987 Trott
4702261 October 27, 1987 Cornell et al.
4729763 March 8, 1988 Henrie
4788975 December 6, 1988 Shturman et al.
4790812 December 13, 1988 Hawkins, Jr. et al.
4792327 December 20, 1988 Swartz
4813930 March 21, 1989 Elliott
4850354 July 25, 1989 McGurk-Burleson et al.
4856529 August 15, 1989 Segal
4895166 January 23, 1990 Farr et al.
4898577 February 6, 1990 Badger et al.
4917102 April 17, 1990 Miller et al.
4923462 May 8, 1990 Stevens
RE33258 July 10, 1990 Onik et al.
4957742 September 18, 1990 Knighton
4964854 October 23, 1990 Luther
4976710 December 11, 1990 Mackin
4985028 January 15, 1991 Isner et al.
5030201 July 9, 1991 Palestrant
5087265 February 11, 1992 Summers
5093877 March 3, 1992 Aita et al.
5104393 April 14, 1992 Isner et al.
5106386 April 21, 1992 Isner et al.
5123904 June 23, 1992 Shimomura et al.
5125924 June 30, 1992 Rudko
5125926 June 30, 1992 Rudko
5133713 July 28, 1992 Huang et al.
5135531 August 4, 1992 Shiber
5152744 October 6, 1992 Krause et al.
5195988 March 23, 1993 Haaga
5197968 March 30, 1993 Clement
5224951 July 6, 1993 Freitas
5242460 September 7, 1993 Klein et al.
5263959 November 23, 1993 Fischell
5269785 December 14, 1993 Bonutti
5273051 December 28, 1993 Wilk
5281218 January 25, 1994 Irman
5285795 February 15, 1994 Ryan et al.
5287861 February 22, 1994 Wilk
5292309 March 8, 1994 Van Tassel et al.
5313949 May 24, 1994 Yock et al.
5323781 June 28, 1994 Ideker et al.
5324284 June 28, 1994 Imran
5330466 July 19, 1994 Imran
5336237 August 9, 1994 Chin et al.
5339799 August 23, 1994 Kami et al.
5342300 August 30, 1994 Stefanadis et al.
5342393 August 30, 1994 Stack
5354310 October 11, 1994 Garnic
5358472 October 25, 1994 Vance
5358485 October 25, 1994 Vance
5366468 November 22, 1994 Fucci et al.
5366490 November 22, 1994 Edwards et al.
5370675 December 6, 1994 Edwards et al.
5379772 January 10, 1995 Imran
5380316 January 10, 1995 Aita et al.
5383884 January 24, 1995 Summers
5389073 February 14, 1995 Imran
5389096 February 14, 1995 Aita et al.
5392917 February 28, 1995 Alpern et al.
5396897 March 14, 1995 Jain et al.
5403334 April 4, 1995 Evans et al.
5409000 April 25, 1995 Imran
5415166 May 16, 1995 Imran
5419777 May 30, 1995 Hofling
5425376 June 20, 1995 Banys et al.
5429144 July 4, 1995 Wilk
5439474 August 8, 1995 Li
5443443 August 22, 1995 Shiber
5456689 October 10, 1995 Kresch et al.
5464395 November 7, 1995 Faxon et al.
5465717 November 14, 1995 Irman et al.
5488958 February 6, 1996 Topel et al.
5492119 February 20, 1996 Abrams
5497784 March 12, 1996 Irman
5505725 April 9, 1996 Samson
5507802 April 16, 1996 Irman
5520634 May 28, 1996 Fox et al.
5527279 June 18, 1996 Irman
5531780 July 2, 1996 Vachon
5551427 September 3, 1996 Altman
5554152 September 10, 1996 Aita
5562694 October 8, 1996 Sauer
5569178 October 29, 1996 Henry
5569254 October 29, 1996 Carson et al.
5569284 October 29, 1996 Young et al.
5575293 November 19, 1996 Miller et al.
5575772 November 19, 1996 Lennox
5575787 November 19, 1996 Abela et al.
5575810 November 19, 1996 Swanson
5578067 November 26, 1996 Ekwall et al.
5584842 December 17, 1996 Fogarty et al.
5588432 December 31, 1996 Crowley
5591159 January 7, 1997 Taheri
5593405 January 14, 1997 Osypka
5601573 February 11, 1997 Fogelbert et al.
5601586 February 11, 1997 Fucci et al.
5601588 February 11, 1997 Tonomura et al.
5606974 March 4, 1997 Castellano et al.
5607421 March 4, 1997 Jeevanandam et al.
5609591 March 11, 1997 Daikuzono
5609621 March 11, 1997 Bonner
5611803 March 18, 1997 Heaven et al.
5613972 March 25, 1997 Lee et al.
5640955 June 24, 1997 Ockuly et al.
5643253 July 1, 1997 Baxter et al.
5651781 July 29, 1997 Grace
5658263 August 19, 1997 Dang et al.
5662124 September 2, 1997 Wilk
5662671 September 2, 1997 Barbut et al.
5665062 September 9, 1997 Houser
5669920 September 23, 1997 Conley
5680860 October 28, 1997 Imran
5683362 November 4, 1997 Rowland et al.
5688234 November 18, 1997 Frisbie
5702412 December 30, 1997 Popov et al.
5709697 January 20, 1998 Ratcliff et al.
5722400 March 3, 1998 Ockuly et al.
5724975 March 10, 1998 Negus et al.
5725521 March 10, 1998 Mueller
5730741 March 24, 1998 Horzewski et al.
5743870 April 28, 1998 Edwards
5755714 May 26, 1998 Murphy-Chutorian
5766163 June 16, 1998 Mueller et al.
5776092 July 7, 1998 Farin et al.
5782823 July 21, 1998 Mueller
5797870 August 25, 1998 March et al.
5807384 September 15, 1998 Mueller
5807401 September 15, 1998 Grieshaber et al.
5814028 September 29, 1998 Swartz et al.
5830210 November 3, 1998 Rudko et al.
5830222 November 3, 1998 Makower
5833715 November 10, 1998 Vachon et al.
5834418 November 10, 1998 Brazeau et al.
5840059 November 24, 1998 March et al.
5846225 December 8, 1998 Rosengart et al.
5851171 December 22, 1998 Gasson
5857995 January 12, 1999 Thomas et al.
5871495 February 16, 1999 Mueller
5873366 February 23, 1999 Chim et al.
5876373 March 2, 1999 Giba et al.
5878751 March 9, 1999 Hussei et al.
5885272 March 23, 1999 Aita et al.
5885276 March 23, 1999 Ammar et al.
5893848 April 13, 1999 Negus et al.
5899874 May 4, 1999 Jonsson
5906594 May 25, 1999 Scarfone et al.
5910150 June 8, 1999 Saadat
5916214 June 29, 1999 Cosio et al.
5921982 July 13, 1999 Lesh et al.
5925012 July 20, 1999 Murphy-Chutorian et al.
5928943 July 27, 1999 Franz et al.
5931848 August 3, 1999 Saadat
5938632 August 17, 1999 Ellis
5941868 August 24, 1999 Kaplan et al.
5941893 August 24, 1999 Saadat
5944716 August 31, 1999 Hektner
5951567 September 14, 1999 Javier, Jr. et al.
5964754 October 12, 1999 Osypka
5964757 October 12, 1999 Ponzi
5968059 October 19, 1999 Ellis et al.
5971993 October 26, 1999 Hussein et al.
5980545 November 9, 1999 Pacala et al.
5980548 November 9, 1999 Evans et al.
5989278 November 23, 1999 Mueller
6030377 February 29, 2000 Linhares et al.
6036677 March 14, 2000 Javier, Jr. et al.
6045530 April 4, 2000 Krueger et al.
6045565 April 4, 2000 Ellis et al.
6051008 April 18, 2000 Saadat et al.
6056743 May 2, 2000 Ellis et al.
6056760 May 2, 2000 Koike et al.
6066126 May 23, 2000 Li et al.
6093177 July 25, 2000 Javier, Jr. et al.
6102887 August 15, 2000 Altman et al.
6106520 August 22, 2000 Laufer et al.
6126654 October 3, 2000 Giba et al.
6165164 December 26, 2000 Hill et al.
6179809 January 30, 2001 Khairkhahan et al.
6197324 March 6, 2001 Crittenden
6224584 May 1, 2001 March et al.
6238389 May 29, 2001 Paddock et al.
6251104 June 26, 2001 Kesten et al.
6270496 August 7, 2001 Bowe et al.
6309370 October 30, 2001 Haim et al.
6322548 November 27, 2001 Payne et al.
6589232 July 8, 2003 Mueller
6613062 September 2, 2003 Leckrone et al.
6620139 September 16, 2003 Plicchi et al.
6638233 October 28, 2003 Corvi et al.
6905476 June 14, 2005 Ponzi
7094201 August 22, 2006 Stokes et al.
20040010231 January 15, 2004 Leonhardt
Foreign Patent Documents
0807412 November 1997 EP
0853921 July 1998 EP
0868923 October 1998 EP
0876796 November 1998 EP
0895752 February 1999 EP
WO 86/03122 June 1986 WO
WO 86/03122 June 1986 WO
WO 92/10142 June 1992 WO
WO 96/25097 August 1996 WO
WO 96/26675 September 1996 WO
WO 96/35469 November 1996 WO
WO 97/10753 March 1997 WO
WO 97/13471 April 1997 WO
WO 98/05307 February 1998 WO
WO 98/17186 April 1998 WO
WO 98/38916 September 1998 WO
WO 98/39045 September 1998 WO
Other references
  • NASA's Jet Propulsion Laboratory, “Swivel-head Sampling Drill Bit,” NASA Tech Briefs, Nov. 1998.
  • PCT Communication—Supplementary European Search Report, Aug. 3, 2001, 3 pages.
  • PCT International Search Report Mar. 18, 1998, 4 pages.
  • PCT Notification of Transmittal of International Preliminary Examination Report, Apr. 15, 1999, 13 pages.
  • PCT Written Opinion, Dec. 23, 1998, 4 pages.
  • Mandrusov, Membrane-Based Cell Affinity Chromatography to Retrieve Viable Cells, Biotechnol, Prob. 1995, 11, 208-213, Artificial Organs Research Laboratory, Department of Chemical Engineering, Material Sciences and Metallurgy, Columbia University, New York, New York 10027, and Lousville, Lousville, Kentucky 40292.
  • Assmus, Tranplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction (TOPCARE-AMI), Clinical Investigation and Reports, Oct. 8, 2002, pp. 3009-3017, Department of Molecular Cardiology and Department of Hematology (H.M., D.H.) University of Frankfurt, Frankfurt, Germany, Circulation availabe at http://www.circulationha.org DOI: 10.1161/01. CIR.0000043246.74879CD.
  • The PMR™ Procedure, http://www.cardiogenesis.com/percutaneous/procedure.html, Jan. 27, 1999.
  • PMR Poduct, Axcis™ PMR. System, http://www.cardiogenesis.com/percutaneous/product.html, Jan. 27, 1999.
  • Cooley, Denton A., M.D. et al., “Transmyocardial Laser Revascularization: Clinical Experience with Twelve-Month Follow-Up,” The Journal of Thoracic and Cardiovascular Surgery, (Apr. 1996), pp. 791-799.
  • Cooley, Denton A., M.D. et al., “Transmyocardial Laser Revascularization: Anatomic Evidence of Long-Term Channel Patency,” Texas heart Institute Journal, vol. 21, No. 3 (1994), pp. 220-224.
  • Fenton II, John W. et al., “Thrombin and Antithrombotics,” Seminars in Thrombosis and Hemostasis, vol. 24, No. 2, 1998, pp. 87-91.
  • Folkman, Judah, “Angiogenic Therapy of the Human Heart,” Circulation, 1998; 97:628-629.
  • Frazier, O.H., M.D., et al., “Myocardial Revascularization With Laser: Preliminary Findings,” Supplement II Circulation, vol. 92, No. 9, (Nov. 1995), pp. II-58-II-65.
  • Hardy, Roger Ian, et al., “A Histologic Study of Laser-Induced Transmyocardial Channels,” Lasers in Surgery and Medicine, (1987), pp. 6:563-573.
  • Henry, Timothy D., “Can We really Grow New Blood Vessels,” The Lancet, vol. 351, Jun. 20, 1998, pp. 1826-1827.
  • Hershey, John E. et al., “Transmyocardial Puncture Revascularization: A Possible Emergency Adjunct to Arterial Implant Surgery,” Geriatrics, (Mar. 1969), pp. 101-108.
  • Horvath; Keith A., M.D., et al., “Recovery and Viability of an Acute Myocardial Infarct After Transmyocardial Laser Revascularization,” Journal of American College of Cardiology, vol. 25, No. 1 (Jan. 1995), pp. 258-263.
  • Horvath, Keith A., M.D., et al., “Transmyocardial Laser Revascularization: Operative Techniques and Clinical Results at Two Years,” The Journal of Thoracic and Cardiovascular Surgery, (May 1996) pp. 1047-1053.
  • Khazei, Hassan A., et al., “Myocardial Canalization: A New Method of Myocardial Revasularization,” The Annals of Thoracic Surgery, vol. 6, No. 2, (Aug. 1968) pp. 163-171.
  • Knighton, David R. et al., “Role of Platelets and Fibrin in the Healing Sequence,” Annals of Surgery, vol. 196, No. 4, Oct. 1982, pp. 379-388.
  • Kohmoto, Takushi, M.D., et al., “Does Blood Flow Through Holmium: YAG Transmyocardial Laser Channels?,” Ann. Thorac. Surg., (1996) pp. 61: 861-868.
  • Kuzela, Ladislaw, et al., “Experimental Evaluation of Direct Transventricular Revascularization,” Journal ofThoracic and Cardiovasuclar Surger, vol. 57, No. 6, (Jun. 1969), pp. 770-773.
  • Lee, Garrett, M.D., “Effects of Laser Irradiation Delivered by Flexible Fiberoptic System on the Left Ventricular Internal Myocardium,” American Heart Journal, (Sep. 1983), pp. 587-590.
  • Losordo, Douglas W. et al., “Gene Therapy for Myocardial Angiogenesis Initial Clinical Results With Direct Myocardial Injection of phVEGF.sub.165 as Sole Therapy for Myocardial Ischemia,” Circulation, 1998; 98: 2800-2804.
  • Maloney, James P. et al., “In Vitro Release of Vascular Endothelial Growth Factor During Platelet Aggregation,” American Physiological Society, H1054-H1061, 1998.
  • Miyazono, Kohei et al., “Platelet-Derived Endothelial Cell Growth Factor,” Progress in Growth Factor Research, vol. 3, 1991, pp. 207-217.
  • Pipili-Synetos, E. et al., “Evidence That Platelets Promote Tube Formation By Endothelial Cells on Matrigel,” British Journal of Pharmacology, vol. 125, 1998, pp. 1252-1257.
  • Simons, Michael et al., “Food for Starving Hearts,” Nature Medicine, vol. 2, No. 5, May 1996, pp. 519-520.
  • Sen, P.K. et al., “Further Studies in Multiple Transmyocardial Acupuncture as a Method of Myocardial Revascularization,” Surgery, vol. 64, No. 5, (Nov. 1968), pp. 861-870.
  • Tsopanoglou, Nikos E. et al., “Thrombin Promotes Angiogenesis By a Mechanism Independent of Fibrin Formation,” American Physiological Society, 0363-6143/93, C1302-1307.
  • Thaning, Otto, “Transmyocardial Laser Revascularisation in South Africa,” SAMJ, vol. 85, No. 8 (Aug. 1995) pp. 787-788.
  • Verheul, Henk M.W. et al., “Platelet: Transporter of Vascular Endothelial Growth Factor,” Clinical Cancer Research, vol. 3, Dec. 1997, pp. 2187-2190.
  • Von Oppell, Ulrich O., “Transmyocardial Laser Revascularisation,” SAMJ, vol. 85, No. 9, (Sep. 1995), p. 930.
  • Wakabayashi, Akio, “Myocardial Boring For the Ischemic Heart,” Arch. Surgery, vol. 95, (Nov. 1967), pp. 743-752.
  • Wartiovaara, Ulla et al., “Peripheral Blood Platelets Express VEGF-C and VEGF Which Are Released During Platelet Activation,” Thromb Haemost, 1998, 80:171-5.
  • Washington Adventist Hospital, “Washington Area Cardiologist Performs First State-of-the-Art Heart Procedure In U.S.,” PR Newswire, Dec. 15, 1999, 2 pages.
  • White, Manuel et al., “Multiple Transmyocardial Puncture Revascularization in Refractory Ventricular Fibrillation due to Myocardial Ischemia,” The Annals of Thoracic Surgery, vol. 6, No. 6, (Dec. 1968), pp. 557-563.
  • A Collection of Abstracts, Society of Thoracic Surgeons, 1999.
Patent History
Patent number: RE42959
Type: Grant
Filed: Sep 17, 2002
Date of Patent: Nov 22, 2011
Assignee: Abbott Cardiovascular Systems Inc. (Santa Clara, CA)
Inventors: Vahid Saadat (Saratoga, CA), John H. Ream (San Jose, CA)
Primary Examiner: Kevin T Truong
Attorney: Blakely, Sokoloff, Taylor & Zafman LLP
Application Number: 10/246,030
Classifications
Current U.S. Class: Angioplasty (606/7); Flow Control (604/30)
International Classification: A61N 5/06 (20060101);